Cas9 Stable Cell Line - Ramos

The Ramos-Cas9 stable cell line is a top-tier immunological model established by integrating the Cas9 nuclease into the human Ramos B lymphoblast cell line. The Ramos cell line was derived from a 3-year-old male patient with Burkitt lymphoma. Unlike Raji cells, Ramos cells do not carry Epstein-Barr virus (EBV) and exhibit a characteristic t(8;14) translocation, leading to the hallmark overexpression of c-Myc. These cells represent the mature B-cell phenotype (IgM+, CD19+, CD20+) and are widely used to study B-cell receptor (BCR) signaling pathways and apoptosis mechanisms. Constitutive expression of Cas9 in Ramos cells provides a highly reproducible and efficient platform for CRISPR-mediated gene editing, ensuring the sustained activity of the editing mechanism. This stable cell line ensures consistent editing function across all cells, making it ideal for high-throughput functional genomics studies in a well-defined B-cell environment.

The primary applications of the Ramos-Cas9 stable cell line are in studying B-cell biology and identifying novel therapeutic targets for B-cell malignancies. Scientists have used this cell line for CRISPR screening to identify genes involved in BCR-mediated activation, cell cycle regulation, and pathways promoting tumor survival. The Ramos-Cas9 cell line is particularly important for constructing homologous clones, enabling studies on how specific gene mutations found in lymphoma patients alter cell signaling and drug sensitivity. Furthermore, it serves as a reliable platform for evaluating the efficacy of novel targeted therapies and investigating the molecular mechanisms of AID-mediated somatic high-frequency mutations and class-switching recombination. The model''s well-defined EBV-negative Burkitt lymphoma background and stable Cas9 expression make it an indispensable resource for enhancing our understanding of human immunology and developing precision oncology strategies.